James N Ingle

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Adjuvant endocrine therapy for postmenopausal women with early breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MH 55905, USA
    Clin Cancer Res 12:1031s-1036s. 2006
  2. doi request reprint Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA Electronic address
    Breast 22:S180-3. 2013
  3. pmc Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Discov 3:812-25. 2013
  4. doi request reprint Pharmacogenomics of endocrine therapy in breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Hum Genet 58:306-12. 2013
  5. pmc Estrogen as therapy for breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 4:133-6. 2002
  6. pmc Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
    James N Ingle
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4674-82. 2010
  7. ncbi request reprint Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
    James N Ingle
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Breast Cancer Res Treat 98:217-22. 2006
  8. ncbi request reprint Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032
    James N Ingle
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:1052-6. 2006
  9. ncbi request reprint Sequencing of hormonal therapy in breast cancer
    James N Ingle
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Breast J 8:332-7. 2002
  10. ncbi request reprint Adjuvant endocrine therapy in postmenopausal breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:480S-5S. 2003

Research Grants

  1. Mayo Clinic Breast Cancer SPORE
    James Ingle; Fiscal Year: 2007

Detail Information

Publications127 found, 100 shown here

  1. ncbi request reprint Adjuvant endocrine therapy for postmenopausal women with early breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MH 55905, USA
    Clin Cancer Res 12:1031s-1036s. 2006
    ....
  2. doi request reprint Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA Electronic address
    Breast 22:S180-3. 2013
    ..The balance of benefit and toxicity favors the use of AIs in the adjuvant setting but the absolute benefit from AIs can be decreased in patients with advancing age or increasing comorbidities. ..
  3. pmc Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Discov 3:812-25. 2013
    ..ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor. The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71. ..
  4. doi request reprint Pharmacogenomics of endocrine therapy in breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Hum Genet 58:306-12. 2013
    ..As will be seen in this review, this has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer. ..
  5. pmc Estrogen as therapy for breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 4:133-6. 2002
    ..Clinical and laboratory data together provide the basis for developing testable hypotheses of management strategies, with the potential of increasing the value of endocrine therapy in women with breast cancer...
  6. pmc Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
    James N Ingle
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4674-82. 2010
    ....
  7. ncbi request reprint Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
    James N Ingle
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Breast Cancer Res Treat 98:217-22. 2006
    ....
  8. ncbi request reprint Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032
    James N Ingle
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:1052-6. 2006
    ..This study was designed to examine the efficacy and toxicity of fulvestrant in patients with disease progression on a third-generation aromatase inhibitor (AI)...
  9. ncbi request reprint Sequencing of hormonal therapy in breast cancer
    James N Ingle
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Breast J 8:332-7. 2002
    ..Multiple clinical trials involving these agents have been conducted which permit an evidence-based approach to the development of a sequencing strategy for treatment of women with breast cancer...
  10. ncbi request reprint Adjuvant endocrine therapy in postmenopausal breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:480S-5S. 2003
    ..However, close attention must be paid to new information as it develops not only related to efficacy but also to other end organ effects...
  11. ncbi request reprint Aromatase inhibitors for therapy of advanced breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Steroid Biochem Mol Biol 95:113-9. 2005
    ..The main area of future investigations for the AIs in premenopausal women will be in the adjuvant therapy setting in combination with suppression of ovarian function...
  12. ncbi request reprint Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Steroid Biochem Mol Biol 86:313-9. 2003
    ..This provides a strong impetus for further study of the aromatase inhibitors in the preoperative setting...
  13. ncbi request reprint Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 10:362S-7S. 2004
    ..Phase II data are available for exemestane and high-dose estrogens, and retrospective data are available for tamoxifen and fulvestrant. Additional clinical trials are needed to determine an optimal sequencing strategy...
  14. doi request reprint Overview of adjuvant trials of aromatase inhibitors in early breast cancer
    James N Ingle
    Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Steroids 76:765-7. 2011
    ..This review will outline the trials that have provided evidence on the value of the aromatase inhibitors in the adjuvant setting as well as the ongoing trials that will expand our knowledge of how to use them most effectively...
  15. pmc Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer
    James N Ingle
    Division of Medical Oncology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:3278-86. 2010
    ..These findings may have implications with regard to efficacy and adverse events and may indicate the need to "individualize" therapy with this drug...
  16. ncbi request reprint Pharmacogenomics of tamoxifen and aromatase inhibitors
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 112:695-9. 2008
    ..Currently, the emphasis is on examining multiple genes (thus pharmacogenomics) in pharmacodynamic and pharmacokinetic pathways in women receiving aromatase inhibitors for breast cancer...
  17. ncbi request reprint Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention
    J N Ingle
    Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 15:28-34. 2001
    ..The emergence of the estrogen genotoxicity hypothesis as a mechanism for breast cancer carcinogenesis provides additional rationale for considering aromatase inhibitors in the chemoprevention setting...
  18. ncbi request reprint Current status of adjuvant endocrine therapy for breast cancer
    J N Ingle
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 7:4392s-4396s; discussion 4411s-4412s. 2001
    ..In premenopausal women, ovarian ablation/suppression has demonstrated efficacy comparable with some chemotherapy regimens, but its role in women receiving chemotherapy remains to be determined...
  19. ncbi request reprint Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer
    J N Ingle
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 5:1642-9. 1999
    ..Estrogen suppression induced by letrozole was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus letrozole was less than expected...
  20. ncbi request reprint Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, 55905, USA
    Clin Cancer Res 11:900s-5s. 2005
    ....
  21. doi request reprint Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17
    J N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 19:877-82. 2008
    ..57, P = 0.00008]. The trial was unblinded and placebo patients were offered letrozole...
  22. pmc Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:5864-8. 2008
    ..We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer...
  23. pmc HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial
    Edith A Perez
    Serene M and Frances C Durling Professor of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 28:4307-15. 2010
    ....
  24. ncbi request reprint A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations
    Sandhya Pruthi
    Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1131-40. 2007
    ..The goal of this article is to provide clinicians who care for women with breast cancer a multidisciplinary, state-of-the art approach to the treatment of these patients...
  25. pmc Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:319-28. 2010
    ..Our findings indicate that two common genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to aromatase inhibitors...
  26. ncbi request reprint A comprehensive examination of CYP19 variation and breast density
    Janet E Olson
    Division of Epidemiology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55901, USA
    Cancer Epidemiol Biomarkers Prev 16:623-5. 2007
  27. ncbi request reprint The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN, 55905, USA
    Breast Cancer Res Treat 101:113-21. 2007
    ....
  28. pmc TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Endocrinol 27:657-70. 2013
    ..TSPYL5 induced CYP19A1 expression and that of many other genes. These studies have revealed a novel mechanism for regulating aromatase expression and plasma E2 concentrations in postmenopausal women with ER(+) breast cancer...
  29. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  30. pmc Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Genet Epidemiol 36:3-16. 2012
    ..Application of our methods to two different GWAS provide guidance on the potential strengths and weaknesses of our proposed gene-set analyses...
  31. pmc Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1stStreet SW, Rochester, MN 55905, USA
    Breast Cancer Res 13:R27. 2011
    ..Here, we characterize the molecular actions of endoxifen in breast cancer cells expressing ERβ and examine its effectiveness as an anti-estrogenic agent in these cell lines...
  32. pmc Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens
    John R Hawse
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 8:e54613. 2013
    ....
  33. ncbi request reprint HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 24:3032-8. 2006
    ..To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab...
  34. doi request reprint Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
    ..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial...
  35. ncbi request reprint A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Cancer Res 12:2080-7. 2006
    ..In the adjuvant treatment of estrogen receptor (ER)-positive breast cancer, additional markers are needed to identify women at high risk for recurrence...
  36. pmc Coprescription of tamoxifen and medications that inhibit CYP2D6
    Kostandinos Sideras
    Department of Oncology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA
    J Clin Oncol 28:2768-76. 2010
    ....
  37. ncbi request reprint Methylenetetrahydrofolate reductase haplotype tag single-nucleotide polymorphisms and risk of breast cancer
    Yvette N Martin
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 15:2322-4. 2006
  38. pmc Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials
    Matthew P Goetz
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 17:6944-51. 2011
    ..Controversy exists regarding the association between CYP2D6 enzyme activity and tamoxifen effectiveness in the adjuvant treatment of invasive breast cancer; however, this association in the primary prevention of breast cancer is unknown...
  39. pmc C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial
    Edith A Perez
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:651-9. 2011
    ....
  40. ncbi request reprint Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252
    Edith A Perez
    Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    Clin Breast Cancer 6:425-32. 2005
    ..The efficacy and tolerability of 2 different schedules of paclitaxel/carboplatin/trastuzumab for HER2-overexpressing metastatic breast cancer (MBC) were evaluated in this parallel multicenter phase II trial...
  41. pmc Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study
    Clive S Grant
    Division of General Surgery, Mayo Clinic, North Central Cancer Treatment Group, Dept of Surgery, 200 1st St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:3620-6. 2009
    ....
  42. pmc Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
    ..In the present study, we set out to determine whether these SNPs might influence cytokine expression and effect more widely, and, if so, to explore the mechanism of TCL1A-related AI-induced side effects...
  43. pmc Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 29:4491-7. 2011
    ....
  44. pmc Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
    J Cell Biochem 113:711-23. 2012
    ..The use of the MC10 antibody, in combination with highly specific antibodies targeting only full-length ERβ, is likely to provide additional discriminatory features in breast cancers that may be useful in predicting response to therapy...
  45. pmc Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model
    Ianko D Iankov
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res Treat 122:745-54. 2010
    ..This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer...
  46. pmc Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain
    John R Hawse
    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mol Endocrinol 22:1579-95. 2008
    ....
  47. ncbi request reprint Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    Patrick C Roche
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Natl Cancer Inst 94:855-7. 2002
    ..The concordance for central HercepTest and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831...
  48. pmc Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen
    Lavakumar Karyampudi
    Department of Immunology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Immunol Immunother 59:161-71. 2010
    ..Patients with breast or ovarian cancer demonstrate pre-existent immune responses to the tumor antigen CEA. The degenerate pool of CEA peptides may be useful for augmenting CD4 T cell immunity...
  49. pmc Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
    Judith A Gilbert
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mol Cancer Ther 7:944-51. 2008
    ....
  50. pmc Aromatase immunoreactivity is increased in mammographically dense regions of the breast
    Celine M Vachon
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res Treat 125:243-52. 2011
    ..45, SD = 0.39) breast tissue (β(H) = 0.45; P < 0.001). Overall, aromatase IR was greater for mammographically dense versus non-dense tissue and may partly explain how MBD influences breast cancer...
  51. pmc Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record
    Guergana K Savova
    Mayo Clinic, Rochester, Minnesota, USA
    J Am Med Inform Assoc 19:e83-9. 2012
    ....
  52. doi request reprint The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 69:1722-7. 2009
    ..These results support the theory that endoxifen is the primary metabolite responsible for the overall effectiveness of tamoxifen in the treatment of ER-positive breast cancer...
  53. ncbi request reprint Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization
    Svetomir N Markovic
    Melanoma Study Group of the Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 29:352-60. 2006
    ....
  54. pmc Functional role of KLF10 in multiple disease processes
    Malayannan Subramaniam
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
    Biofactors 36:8-18. 2010
    ....
  55. pmc Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus
    Ianko D Iankov
    Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Mol Ther 20:1139-47. 2012
    ..These data suggest that potent immunomodulators of bacterial origin, such as H. pylori NAP, can enhance the antitumor effect of oncolytic viruses and support the feasibility and potential of a combined viroimmunotherapy approach...
  56. doi request reprint Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer
    Sejal S Shah
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Hum Pathol 41:103-6. 2010
    ..Clinical studies are needed to determine whether the updated guidelines are better at predicting response to anti-human epidermal growth factor receptor 2 therapy...
  57. doi request reprint Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors
    Sook Shin
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Cell Biochem 105:866-74. 2008
    ..Furthermore, given its expression pattern and enzymatic function in nucleotide metabolism, Rcl presents itself as a novel target in breast cancer therapy via modulation of its activity by small molecule drugs...
  58. ncbi request reprint A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932
    Edith A Perez
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Oncology 69:117-21. 2005
    ..A phase II multi-institutional clinical trial conducted to evaluate the efficacy and tolerability of docetaxel and carboplatin as first-line therapy for women with metastatic breast cancer...
  59. ncbi request reprint Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
    Edith A Perez
    North Central Cancer Treatment Group, Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 22:3700-4. 2004
    ....
  60. ncbi request reprint Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue
    Monica M Reinholz
    Division of Experimental Pathology, Department of Biochemistry, Mayo Clinic College of Medicine, Rochester, MN, USA
    Breast Cancer Res Treat 86:75-88. 2004
    ..Further investigation is necessary to validate the ability of these genes to discriminate between different populations of breast cancer patients...
  61. pmc Tissue composition of mammographically dense and non-dense breast tissue
    Karthik Ghosh
    Department of Medicine, Mayo Clinic College of Medicine, Charlton 6 239, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res Treat 131:267-75. 2012
    ..Studies of both epithelial and stromal components are important in understanding the association between mammographic density and breast cancer risk...
  62. pmc SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen
    Ann M Moyer
    Mayo Clinic, Rochester, MN 55905, USA
    Pharmacogenomics 12:1535-43. 2011
    ....
  63. ncbi request reprint Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole
    Jacqueline M Lafky
    Tumor Biology Program, Cancer Center Statistics Unit, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    Cancer Res 65:3059-62. 2005
    ....
  64. pmc Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging
    Rajini Katipamula
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:4082-8. 2009
    ..We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN...
  65. pmc CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8
    Matthew P Goetz
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 19:500-7. 2013
    ..Controversy exists about CYP2D6 genotype and tamoxifen efficacy...
  66. ncbi request reprint A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
    Svetomir N Markovic
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Clin Oncol 30:303-9. 2007
    ..We conducted a phase II trial evaluating the clinical efficacy of ABT-510 and its effects on biomarkers of angiogenesis and immunity in patients with metastatic melanoma (MM)...
  67. ncbi request reprint Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer
    Monica M Reinholz
    Divisions of Experimental Pathology and Biostatistics, and Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Cancer Res 11:3722-32. 2005
    ..We examined the feasibility of using molecular characterization of circulating tumor cells as a method for early detection of breast cancer...
  68. ncbi request reprint Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 23:9312-8. 2005
    ..Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown...
  69. ncbi request reprint Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas
    Dylan V Miller
    Department of Anatomic Pathology, Mayo Clinic, Rochester, MN 55906, USA
    Mod Pathol 17:756-64. 2004
    ..These data add support to the assertion that prognostic groups of breast carcinoma are reflected in distinguishable expression profiles of a limited set of genes...
  70. pmc Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score
    Arif H Kamal
    Division of Medical Oncology, Duke Comprehensive Cancer Center, Durham, North Carolina, USA
    Oncologist 16:1359-66. 2011
    ..Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit. We explored the ability of oncologists to predict the RS using standard prognostic criteria...
  71. pmc A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches
    Janet E Olson
    Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Breast Cancer Res Treat 102:237-47. 2007
    ..We recently published resequencing data on 88 polymorphisms identified in that gene. The hypothesis tested in this study was that polymorphisms, or haplotypes, in CYP19 are related to risk of breast cancer...
  72. pmc A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites
    Monica M Reinholz
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55906, USA
    Bone 47:12-22. 2010
    ..53). These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for TIBD...
  73. ncbi request reprint Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial
    Patrick A Burch
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 28:195-200. 2005
    ..This 2-stage, phase II cooperative group trial examined the efficacy and toxicity of 1000 mg/m2 gemcitabine plus 25 mg/m2 cisplatin weekly for 3 weeks and repeated every 28 days for patients with previously treated metastatic breast cancer...
  74. ncbi request reprint HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Mayo Clin Proc 77:148-54. 2002
    ..To evaluate amplification of the HER-2/neu gene by fluorescence ir situ hybridization (FISH) in tumors with weakly positive (2+) immunohistochemical staining...
  75. ncbi request reprint A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis
    Sandhya Pruthi
    Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:999-1012. 2007
    ....
  76. pmc TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype
    Michael K Asiedu
    Department of Immunology and Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 71:4707-19. 2011
    ....
  77. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  78. ncbi request reprint Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR
    Monica M Reinholz
    Division of Experimental Pathology, Mayo Clinic Rochester, MN, USA
    Breast Cancer Res Treat 74:255-69. 2002
    ....
  79. ncbi request reprint Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis
    J N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905
    Cancer 67:886-91. 1991
    ..05). Although these data require confirmation in a prospective randomized trial, they suggest that there is a substantive therapeutic advantage for TAM plus FLU over TAM alone in elderly women with ER of 10 fmol or greater...
  80. ncbi request reprint Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy
    Thomas E Witzig
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:1085-91. 2002
    ..To examine the feasibility for identifying and enumerating cytokeratin positive (CK+) cells in the peripheral blood of breast cancer patients...
  81. ncbi request reprint Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue
    Gregory G Reinholz
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
    Breast Cancer Res Treat 71:257-68. 2002
    ..In contrast, the inhibition of MDA-MB-231 cell proliferation by the bisphosphonates appears to be through mechanisms other than inhibition of the mevalonate pathway...
  82. ncbi request reprint Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 106:375-82. 2006
    ..Patients with metastatic melanoma (MM) have very few therapy options. Based on reports of responses to paclitaxel and carboplatin (PC), 31 patients with MM were treated with PC...
  83. ncbi request reprint Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
    Edith A Perez
    St Michael s Hospital, Toronto, Canada
    J Clin Oncol 24:3629-35. 2006
    ..17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen...
  84. ncbi request reprint Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells
    Frank J Secreto
    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Cell Biochem 101:1125-47. 2007
    ..Hs578T ER expressing cell-lines provide a unique BC model system, permitting the comparison of ERalpha, ERbeta, and ERbetacx actions in the same cell-line...
  85. ncbi request reprint A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer
    Cari J McDonald
    Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:177-84. 2006
    ..Trackable measles virus derivatives merit further exploration in breast cancer treatment...
  86. ncbi request reprint Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Clin Oncol 22:2849-55. 2004
    ..Previous clinical trials suggested that irinotecan might have such activity. We conducted this multicenter phase II study to assess efficacy and tolerability of two irinotecan schedules...
  87. ncbi request reprint Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen
    C M Vachon
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    Breast 16:204-10. 2007
    ..Results were similar for longitudinal change (-0.68% per year, LET; -0.12% per year, PLAC (P=0.23)). Breast density does not appear to be a clinically relevant biomarker in women who already have low PD following 5 years of TAM...
  88. ncbi request reprint The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug
    D L Ahmann
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905
    J Clin Oncol 5:1928-32. 1987
    ..Serious consideration should be given to the assessment of new agents as first-line therapy, particularly should they have a unique mode of action or lessened morbidities or toxicities...
  89. ncbi request reprint A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer
    E A Perez
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Ann Oncol 13:1225-35. 2002
    ....
  90. ncbi request reprint Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy
    H J Long
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905
    Am J Clin Oncol 11:524-7. 1988
    ..Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin...
  91. ncbi request reprint Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer
    J N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN
    J Clin Oncol 6:825-31. 1988
    ....
  92. ncbi request reprint Complications of therapy and a diagnostic dilemma case. Case 3. Diagnostic dilemma: sarcoidosis simulating metastatic malignancy
    Paul Haluska
    Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 21:4653-4. 2003
  93. ncbi request reprint TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors
    Colleen S Sinclair
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 62:3587-91. 2002
    ..TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors...
  94. ncbi request reprint A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
    C X Ma
    Mayo Clinic and Foundation, Department of Oncology and Medicine, Rochester, MN 55905, USA
    Ann Oncol 17:226-31. 2006
    ..This phase II study was undertaken to define the efficacy and toxicity of pemetrexed in combination with gemcitabine in patients with metastatic breast cancer...
  95. ncbi request reprint Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:865-71. 2001
    ..In conclusion, ALC > or = 500 cells/microl on day 15 post-ASCT was associated with significantly better survival in patients with metastatic breast cancer, suggesting the importance of early immune recovery post-ASCT in these patients...
  96. ncbi request reprint Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure
    J C Buckner
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905
    Am J Clin Oncol 12:384-6. 1989
    ..We conclude that menogaril does not appear to be useful at this dose and schedule in the treatment of metastatic sarcomas despite the use of near maximal doses in patients with no prior chemotherapy exposure...
  97. ncbi request reprint Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors
    G Wu
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 61:4951-5. 2001
    ..We present correlative amplification and overexpression studies for the FLJ21316 and Hs.6649 genes suggesting a role for these candidates as amplification-dependent oncogenes...
  98. ncbi request reprint 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes
    G J Wu
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 60:5371-5. 2000
    ..Our data show that this region contains at least four independent targets of amplification, which suggests that there is considerable variability in the structure of the 17q23 amplicon...
  99. pmc Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors
    J R Hawse
    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Cell Biochem 103:383-92. 2008
    ..In this prospectus, we present known and potential roles of TIEG, Runx2, and other transcription factors as important mediators of signaling between these two pathways...
  100. ncbi request reprint Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196
    Stanley Zucker
    Veterans Affairs Medical Center, Northport, NY State University Hospital of New York, Stony Brook, USA
    Clin Breast Cancer 6:525-9. 2006
    ....
  101. ncbi request reprint Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...

Research Grants2

  1. Mayo Clinic Breast Cancer SPORE
    James Ingle; Fiscal Year: 2007
    ....